SuperworthPetmed Express profit margin PETS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −17.3%
- Operating margin, 12 months
- −18.2%
- Net margin on a year earlier
- +3.5 pts
- Peer median
- 6.8%
Over the twelve months to Jun 30, 2026, Petmed Express kept −17.3% of its revenue as net profit, with an operating margin of −18.2% and a gross margin of 27.9%.
Five years earlier its net margin was 9.1%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | −32.0% | −32.8% | 28.1% |
| FY2025 | −2.8% | −0.7% | 30.5% |
| FY2024 | −2.7% | −2.9% | 28.0% |
| FY2023 | 2.0% | 2.4% | 27.6% |
| FY2022 | 6.9% | 9.4% | 28.7% |
| FY2021 | 9.9% | 12.2% | 29.1% |
| FY2020 | 9.1% | 10.9% | 28.6% |
| FY2019 | 13.3% | 16.3% | 33.6% |
| FY2018 | 13.6% | 19.0% | 35.7% |
| FY2017 | 9.6% | 15.0% | 31.8% |
| FY2016 | 8.8% | 13.8% | 32.5% |
| FY2015 | 7.6% | 12.0% | 33.2% |
| FY2014 | 7.7% | 12.1% | 33.3% |
| FY2013 | 7.5% | 11.9% | 33.9% |
| FY2012 | 7.0% | 10.9% | 33.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q1 FY27 | −17.3% | +3.5 pts | −18.2% | |
| Q4 FY26 | −32.0% | −29.2 pts | −32.8% | |
| Q3 FY26 | −34.7% | −34.8 pts | −31.6% | |
| Q2 FY26 | −27.8% | −27.4 pts | −24.7% | |
| Q1 FY26 | −20.8% | −19.9 pts | −18.9% | |
| Q4 FY25 | −2.8% | −0.1 pts | −0.7% | |
| Q3 FY25 | 0.1% | +1.1 pts | 0.3% | |
| Q2 FY25 | −0.4% | −0.1 pts | −0.8% | |
| Q1 FY25 | −1.0% | −1.5 pts | −0.6% | |
| Q4 FY24 | −2.7% | −4.7 pts | −2.9% | |
| Q3 FY24 | −1.0% | −5.2 pts | −1.6% | |
| Q2 FY24 | −0.3% | −6.0 pts | −0.8% |
Against its peers
Companies in Healthcare nearest Petmed Express' size, closest first, today.
| Company | Profit margin |
|---|---|
| PETSPetmed Express | −17.3% |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Petmed Express
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.